RTP Mobile Logo
Lung Cancer Update, Issue 2, 2015
Released December 2015

Featuring interviews with Drs Lecia V Sequist, Gregory J Riely, Sarah B Goldberg and Ronald B Natale. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Lung cancer is the leading cause of cancer mortality in the United States for both men and women, resulting in more deaths than breast, prostate, colon and pancreatic cancer combined. Progress in the screening, prevention and treatment of this disease has been limited, and approximately 85% of patients who develop lung cancer will die of it. Traditional chemotherapy, surgery and radiation therapy have had a modest effect on long-term outcomes. However, the advent of biologic agents in lung cancer has led to recent improvements in disease-free and overall survival in select patient populations. Published results from ongoing and completed studies lead to the continual emergence of novel therapeutic strategies and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing clinician must be well informed of these advances. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical and radiation oncologists with the formulation of up-to-date clinical management strategies for the care of patients with lung cancer.

    LEARNING OBJECTIVES

    • Develop an evidence-based approach to the selection of induction and maintenance biologic therapy and/or chemotherapy for patients with advanced non-small cell lung cancer.
    • Integrate newly approved agents for treatment in second- or later-line settings.
    • Formulate an approach to incorporate newly approved checkpoint inhibitors into the treatment algorithm for patients with metastatic NSCLC.
    • Employ an understanding of next-generation sequencing, and determine its clinical and/or research applicability for patients with metastatic lung cancer.
    • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors, and identify therapeutic options in this setting.
    • Identify distinct subtypes of adenocarcinoma of the lung — including those with EGFR mutations, EML4-ALK gene fusions, ROS1 gene rearrangements and other recently identified driver mutations — and the approved and investigational treatment options for patients with these genetic abnormalities.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains both audio and print components.

    CME credit is no longer available for this issue



    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SequistConsulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Genentech BioOncology, Merrimack Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Taiho Oncology Inc. Dr RielyConsulting Agreement: Novartis Pharmaceuticals Corporation; Contracted Research: GlaxoSmithKline, Infinity Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology. Dr GoldbergAdvisory Committee: Clovis Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc. Dr NataleAdvisory Committee: Genentech BioOncology, Roche Laboratories Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Lilly; Other: Spouse employed by AstraZeneca Pharmaceuticals LP.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Clovis Oncology, Foundation Medicine, Genentech BioOncology, Lilly, Merck and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2015
    Expiration date: December 2016

Acknowledge and close

Listen to audio:
Lung Cancer Update, Issue 2, 2015
Released December 2015

Featuring interviews with Drs Lecia V Sequist, Gregory J Riely, Sarah B Goldberg and Ronald B Natale. (Text and Audio Content)

Read print: